Posted 7th October 2019 by Joshua Sewell
The sourcing of natural plant-based compounds is becoming a worldwide bottleneck. The Greenhouse Pharmacy programme of Wageningen University & Research builds new chains between high-tech horticulture and cosmeceutical companies for reliable sourcing of pesticide-free natural plant compounds.
Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
Posted 23rd August 2019 by Jane Williams
The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.
Posted 9th August 2019 by Jane Williams
Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.
Posted 19th July 2019 by Jane Williams
Population increases and patterns of consumption will put pressure on animal protein supply and price over the coming decades. Plant proteins are a viable alternative, but have a lower digestibility then animal proteins.
Posted 15th July 2019 by Joshua Sewell
Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides from Karoline Faust, Dirk Hadrich, Lesley Hoyles & Jos Seegers available.
Posted 5th July 2019 by Jane Williams
Fecal microbiota transplant (FMT) is probably the microbiome based therapy that has received the most media attention. It seems journalists love to talk about poo.
This has given momentum to research in the field. As the amount of trial data and fear of antibiotic resistance grows, FMT is now a much more common treatment for conditions like clostridioides difficile infection (CDI).
Posted 24th June 2019 by Joshua Sewell
Following the Skin Microbiome & Cosmeceuticals Congress: Europe, we have made the following presentation slides from Richard Andrews, Ingmar Claes, Marie Drago & Maya Ivanjesku available.